Enliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increase – What’s Next?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares saw unusually-strong trading volume on Friday . Approximately 1,147,349 shares traded hands during trading, a decline of 1% from the previous session’s volume of 1,154,353 shares.The stock last traded at $42.6360 and had previously closed at $40.36.

Enliven Therapeutics News Summary

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: Enliven reported updated Phase 1 ENABLE trial data for ELVN-001 in previously treated chronic myeloid leukemia, showing encouraging response rates, a favorable safety profile, and continued momentum for its clinical program. Article Title
• Positive Sentiment: The company also said it reached alignment with the FDA on key Phase 3 design elements, including the recommended dose and patient population for the upcoming ENABLE-2 trial, reducing regulatory uncertainty around the program. Article Title
• Neutral Sentiment: Enliven discussed the updated Phase 1 ENABLE trial data in a presentation/transcript, reinforcing investor focus on the clinical details behind the recent share move. Article Title
• Neutral Sentiment: The company priced an upsized public offering of common stock and pre-funded warrants, raising roughly $400 million, which strengthens the balance sheet but may dilute existing shareholders. Article Title
• Negative Sentiment: Enliven also initially announced the offering at a lower size before upsizing it, underscoring the near-term dilution overhang that can pressure the stock even amid positive trial news. Article Title

Analysts Set New Price Targets

A number of analysts have weighed in on ELVN shares. Guggenheim started coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. HC Wainwright increased their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. The Goldman Sachs Group increased their target price on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus began coverage on Enliven Therapeutics in a research note on Tuesday, June 9th. They set a “buy” rating and a $60.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $61.50.

Enliven Therapeutics Trading Up 14.3%

The firm has a market capitalization of $2.81 billion, a PE ratio of -27.62 and a beta of 0.29. The business has a 50 day moving average price of $41.47 and a 200-day moving average price of $30.72.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This trade represents a 16.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. HighVista Strategies LLC increased its stake in Enliven Therapeutics by 83.1% in the 3rd quarter. HighVista Strategies LLC now owns 259,135 shares of the company’s stock valued at $5,304,000 after purchasing an additional 117,619 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in Enliven Therapeutics during the third quarter worth $334,000. Polar Capital Holdings Plc increased its position in Enliven Therapeutics by 13.5% during the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after buying an additional 418,673 shares in the last quarter. Spruce Street Capital LP purchased a new position in Enliven Therapeutics during the fourth quarter worth $6,870,000. Finally, AXQ Capital LP purchased a new position in Enliven Therapeutics during the fourth quarter worth $219,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.